United Therapeutics Corporation UTHR
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing innovative therapies for patients with rare diseases, primarily pulmonary arterial hypertension (PAH) and other pulmonary conditions. The company operates as a public benefit corporation, emphasizing its commitment to both shareholder value and broader social good. Its business model centers on researching, developing, manufacturing, and marketing pharmaceutical products, with a portfolio that includes Tyvaso (in both dry powder and nebulized forms), Remodulin, Orenitram, Unituxin, and Adcirca. These products are prescribed for serious conditions like PAH, pulmonary hypertension associated with interstitial lung disease (PH-ILD), and high-risk neuroblastoma. The company serves patients and healthcare providers globally, generating revenue primarily through product sales in the United States and select international markets, supported by ongoing research and development efforts to expand its therapeutic pipeline.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.